Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This grant funds a student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. This student is working under the supervision of a senior fellow to validate newly discovered immunotherapy targets in AML. The student is using molecular biology techniques to test top 20-30 candidate genes for expression in childhood AML. Validated genes will be used for further immunotherapy development.

This grant funds two undergraduate students to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Project 1: The current treatment strategy for brainstem gliomas is radiotherapy alone, as neurosurgery is not practical due to nearby vital structures. These researchers hypothesize that the development of therapeutics to radiosensitize cancer cells will increase DNA damage, leading to enhanced tumor cell death and ultimately an improvement in patient survival. To investigate the mechanisms of radiosensitization in brainstem gliomas, the student is assisting in utilizing models lacking the DNA damage response protein, ATM, or molecular inhibitors of ATM. The focus will be to investigate how the spectrum of mutations in tumors affects radiosensitization in the absence of functional ATM. Project 2: Rhabdomyosarcoma (RMS) is the most common connective tissue cancer of childhood. The alveolar variant (ARMS) is particularly hard to cure. A common genetic error in ARMS is the mutant protein PAX3-FOXO1, which turns on cellular programs that tell ARMS cells to keep dividing. However, PAX3-FOXO1 is not a good drug target and it does not work alone – it physically interacts with other proteins that carry out its cancer-causing instructions. Recently a team of three labs including this one collaborated to identify such proteins. One of the top discoveries was a protein called CDK8. Not much is known about the job of CDK8 in ARMS, this student will help reveal new information about ARMS.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. T-cell acute lymphoblastic leukemia is a deadly pediatric cancer that requires the use of highly toxic treatment. Doctors still do not know the mechanisms that lead to development of this type of leukemia. This award will train a medical student to perform experiments to identify novel targets for treatment and to help us understand the mechanisms that regulate activities of genes in T-cell leukemia.

This grant funds a student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. B cell acute lymphoblastic leukemia is the most common pediatric cancer. The most deadly subtype of this disease has high levels of the CRLF2 protein. Leukemia cells of this type can be killed when treated with high doses of a naturally occurring molecule in the body. This molecule shuts down cancer causing signals produced by CRLF2. This award will provide resources for a medical student to perform experiments to help us understand the mechanisms that this molecule uses to exerts its anti-leukemia effects so that it can be developed as a new treatment for high-risk leukemia.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Diffuse large B-cell lymphoma (DLBCL) makes up 10-20% of pediatric non-Hodgkin lymphomas. Although its prognosis is improving, it requires up to six months of intensive chemotherapy. Abnormal lymphocytes in DLBCL have high energy demands, so if we could exhaust their energy source, we could arrest abnormal B cell proliferation. This project aims to develop novel, targeted therapy, by depleting energy reserve for B cells, in treating childhood blood cancers.

This grant funds a graduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Neuroblastoma (NB) is an early childhood cancer for which more effective therapies are urgently needed. Immunotherapy has been promising for blood cancers, but in solid tumors like NB, immune cells must compete with tumors for limited nutrients to sustain their function. In NB tumors, these researchers found a high frequency of a type of tumor-killing T cell with unique functional properties that may effectively shrink tumors and improve patient survival. The student is assisting in activating these cells in neuroblastoma tumor models and investigate their cellular properties, with the goal of providing a foundation for more informed immunotherapy of NB and other solid tumors.

This grant funds an undergraduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Diffuse intrinsic pontine glioma (DIPG) is an aggressive pediatric cancer with 10% overall survival 2 years from diagnosis. K27M mutations within histone H3 are the hallmark of DIPG. Panobinostat, a drug targeting epigenetic changes, has shown some promise in DIPG by multiple groups. These researchers' genomic analysis of DIPG cell lines shows that the cancer may be driven by LIN28. DFMO (a-difluoromethylornithine) decreases LIN28 protein levels in neuroblastoma and may be effective in treating DIPG. Therefore, the hypothesis is that co-treatment of DIPG with DFMO and panobinostat will result in increased cell death in DIPG and be an option for patients.

This grant funds an undergraduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Raman spectroscopy (RESpect) is an innovative tool that can be applied to biological specimens to obtain RESpect fingerprints of cancer tissue. RESpect signatures will be obtained from different childhood cancer tissues using the standard RESpect tool in the lab and compare them to the RESpect fingerprints that are obtained from a portable RESpect probe. Applying RESpect technology using a portable RESpect probe has the exciting potential that a portable probe could be used in the clinical setting to quickly assess whether a child might need further assessment to determine if a cancer is present. The St. Baldrick’s Foundation Summer Fellow is collaborating with physicians, engineers and scientists with the potential to make an important contribution on discovering a novel application of RESpect technology.

This grant funds a graduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. HPV vaccination is an important but underutilized tool to ensure the long-term health of childhood and adolescent cancer survivors. Survivors of childhood and adolescent cancers are at higher risk for HPV-related health risks, including HPV-related cancers, than the general population. Unfortunately, their rate of HPV vaccination is much lower than the general population. This study will explore communication strategies related to the HPV vaccine among survivors being seen for follow-up care in an oncology setting. Interviews will be conducted with survivors (ages 18-26) as well as parents of survivors to understand their concerns about and barriers to HPV vaccination and to create specific communication strategies for oncology providers to discuss the HPV vaccine with survivors.

This grant funds two students to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Project 1: There is tremendous excitement surrounding immune checkpoint inhibitor therapies. However, debate continues regarding whether pediatric cancers can benefit from such approaches, as immune checkpoint expressions are often variable and low on pediatric tumors. The student will investigate molecular signaling crosstalk, thereby providing new molecular targets for immune checkpoint blockade for childhood cancers. Project 2: Osteosarcoma (OS) is the most common malignant primary bone cancer in the pediatric and adolescent population, with about 20% of these patients presenting with pulmonary metastasis at diagnosis, while about 30% develop lung metastasis (Lung OS) after therapy initiation, accounting for most of the OS-related mortality. The SBF summer fellow will investigate the how integrin signaling associated with this.

This grant funds an undergraduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. In this summer project in the Ruggero lab, the student will learn and employ cutting edge biological techniques to identify proteins that drive medulloblastoma, focusing on specific proteins whose abundance is regulated by MYC genes.